Contribute Try STAT+ Today

Top of the morning to you and a fine one, it is. Moderate temperatures and clear skies are enveloping the Pharmalot campus this morning, a pleasant respite from the mugginess of the past couple of days. Nonetheless, nothing will stop us from reaching for a steaming cup of stimulation. Our choice today is cinnamon hazelnut, for those tracking this sort of thing. After all, the neurons need a little help. And since no prescription is required, so much the better. Now, though, on to another busy day with a few tidbits to devour. Enjoy, and good luck. …

Acting Food and Drug Administration Commissioner Janet Woodcock acknowledged her agency may have misstepped in its handling of its polarizing approval of a new Alzheimer’s drug from Biogen (BIIB), STAT tells us. She was emphatic in defending the therapy and the agency approval, but said “it’s possible that the process could have been handled in a way that would have decreased the amount of controversy involved. Was the process done exactly the best that it could be? Possibly not.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment